Literature DB >> 22168650

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Alexander Niessner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22168650     DOI： 10.1056/NEJMc1112233

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Small-Bowel Lesions in Patients Taking Direct Oral Anticoagulants Detected Using Capsule Endoscopy.

Authors:  Minoru Yamaoka; Hiroyuki Imaeda; Naoki Hosoe; Kazuaki Yoneno; Ryu Kanno; Takashi Mitsufuji; Takahiro Sasaki; Yuji Akiyama; Hideki Ohgo; Yuichi Morohoshi; Takanori Kanai; Toshimasa Yamamoto; Toshihide Mimura; Haruhiko Ogata; Nobuo Araki; Keiji Yamamoto; Hidetomo Nakamoto
Journal:  Gastroenterol Res Pract       Date:  2020-08-11       Impact factor: 2.260

Review 2.  Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors:  Natalie J Carter; Greg L Plosker
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

3.  Safety of Acupuncture in Patients Taking Newer Oral Anticoagulants: A Retrospective Chart Review Study.

Authors:  Seungwon Kwon; Woo-Sang Jung; Seungbo Yang; Chul Jin; Seung-Yeon Cho; Seong-Uk Park; Sang-Kwan Moon; Jung-Mi Park; Chang-Nam Ko; Ki-Ho Cho; Min-Jeong Park
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-10       Impact factor: 2.629

4.  Non-synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban.

Authors:  Ming Zhao; Qiang Zhang; Xizi Wang; Qianqian Zhang; Conghui Tian; Rongrong Li; Xiaodong Jia; Mingliang Gu; Liping Yang
Journal:  Clin Transl Sci       Date:  2021-12-13       Impact factor: 4.438
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.